These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 23793165)
1. Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. Bell RJ; Schwarz M; Fradkin P; Robinson PJ; Davis SR Menopause; 2013 Jul; 20(7):721-6. PubMed ID: 23793165 [TBL] [Abstract][Full Text] [Related]
2. Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Bell RJ; Fradkin P; Schwarz M; Davis SR Menopause; 2013 Jan; 20(1):15-21. PubMed ID: 22948136 [TBL] [Abstract][Full Text] [Related]
3. Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Davis SR; Panjari M; Robinson PJ; Fradkin P; Bell RJ Menopause; 2014 Oct; 21(10):1075-81. PubMed ID: 24618765 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524 [TBL] [Abstract][Full Text] [Related]
6. Duration of adjuvant endocrine therapy of breast cancer: how much is enough? Ward JH Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743 [TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664 [TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
9. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Gradishar WJ Oncology; 2005; 69(1):1-9. PubMed ID: 16088229 [TBL] [Abstract][Full Text] [Related]
10. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T; Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060 [TBL] [Abstract][Full Text] [Related]
12. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526 [TBL] [Abstract][Full Text] [Related]
13. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Forbes JF Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270 [TBL] [Abstract][Full Text] [Related]
14. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. Dodwell D; Williamson D Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236 [TBL] [Abstract][Full Text] [Related]
15. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369 [TBL] [Abstract][Full Text] [Related]
16. [Current adjuvant endocrine treatment of breast cancer]. Dedes KJ; Gabriel N; Fink D Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529 [TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy for early breast cancer. Hussain SA; Williams S; Stevens A; Rea DW Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321 [TBL] [Abstract][Full Text] [Related]
18. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595 [TBL] [Abstract][Full Text] [Related]
19. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]